Prospects for the use of bovhyaluronidase azoxymer in the post-COVID period after a severe COVID-19: A clinical case

Abstract

Fibrotic changes in lung tissues after coronavirus disease 2019 (COVID-19) are receiving increasing attention. Current tasks for the medical community include not only minimizing the effects on etiotropic factors and increasing the body’s resistance to the damaging effects of viruses but also minimizing the number of complications and in the long term reducing morbidity and improving the prognosis and quality of life of patients after a severe viral infection.

The aim of this study was to describe a clinical case of the effectiveness of bovhyaluronidase azoxymer in the post-COVID period after a severe COVID-19.

A 46-year-old patient was diagnosed with COVID-19, which manifested as an acute respiratory viral infection in the clinic. She was hospitalized in a specialized department. Computed tomography noted 80% of lung damage, and oxygen saturation decreased to 70%. She was treated with antibiotics, antiviral drugs, anticoagulants, and hormones. After 1 month, she was discharged with improvement, and residual effects of lung damage (56%). In the post-hospital period, bovhyaluronidase azoximer for 25 days was prescribed. Clinical, radiological, laboratory, and clinical applied in a hospital.

On computed tomography, no signs of infiltrative changes in the lungs and signs of pneumofibrosis, a picture of viral pneumonia, were noted.

The case highlights the positive action of bovhyaluronidase azoxymer as an immunomodulatory and antifibrosing agent.

Keywords

pneumonia / COVID-19 / pneumofibrosis / bovhyaluronidase azoximer / clinical application

References

[1] Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med. 2020;2020:175964. DOI: 10.1155/2020/6175964

[2] Ojo A.S., Balogun S.A., Williams O.T., Ojo O.S. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies // Pulm Med. 2020. Vol. 2020. ID 6175964. DOI: 10.1155/2020/6175964

[3] Schwensen HF, Borreschmidt LK, Storgaard M, et al. Fatal pulmonary fibrosis: a post-COVID-19 autopsy case. J Clin Pathol. 2020;74(6):400–402. DOI: 10.1136/jclinpath-2020- 206879

[4] Schwensen H.F., Borreschmidt L.K., Storgaard M., et al. Fatal pulmonary fibrosis: a post-COVID-19 autopsy case // J Clin Pathol. 2020. Vol. 74, No. 6. P. 400–402. DOI: 10.1136/jclinpath-2020- 206879

[5] Fang Y, Zhou J, Ding X, et al. Pulmonary fibrosis in critical ill patients recovered from COVID-19 pneumonia: Preliminary experience. Am J Emerg Med. 2020;38(10):2134–2138. DOI: 10.1016/j.ajem.2020.05.120

[6] Fang Y., Zhou J., Ding X., et al. Pulmonary fibrosis in critical ill patients recovered from COVID-19 pneumonia: Preliminary experience // Am J Emerg Med. 2020. Vol. 38, No. 10. P. 2134–2138. DOI: 10.1016/j.ajem.2020.05.120

[7] Faverio P, De Giacomi F, Bonaiti G, et al. Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights. Int J Med Sci. 2019;16(7):967–980. DOI: 10.7150/ijms.32752

[8] Faverio P., De Giacomi F., Bonaiti G., et al. Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights // Int J Med Sci. 2019. Vol. 16, No. 7. P. 967–980. DOI: 10.7150/ijms.32752

[9] McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? J Physiol Lung Cell Mol Physiol. 2021;320(2):L257–L265. DOI: 10.1152/ajplung.00238.2020

[10] McDonald L.T. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? // J Physiol Lung Cell Mol Physiol. 2021. Vol. 320, No. 2. P. L257–L265. DOI: 10.1152/ajplung.00238.2020

[11] Lu Z-H, Yang C-L, Yang G-G, et al. Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial. Infect Dis Poverty. 2021;10(1):31. DOI: 10.1186/s40249-021-00813-8

[12] Lu Z.-H., Yang C.-L., Yang G.-G., et al. Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial // Infect Dis Poverty. 2021. Vol. 10, No. 1. ID 31. DOI: 10.1186/s40249-021-00813-8

[13] Voennov OV, Zagrekov VI, Boyarinov GA, et al. Mechanisms of development of lung injury in patients with novel coronavirus infection (literature review). Medical Almanac. 2020;(3):15–26. (In Russ.)

[14] Военнов О.В., Загреков В. И., Бояринов Г.А., и др. Механизмы развития легочного повреждения у пациентов с новой коронавирусной инфекцией (обзор литературы) // Медицинский альманах. 2020. № 3. С. 15–26.

[15] Vitiello A, Pelliccia C, Ferrara F. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. SN Compr Clin Med. 2020;2:1709–1712. DOI: 10.1007/s42399-020-00487-7

[16] Vitiello A., Pelliccia C., Ferrara F. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy // SN Compr Clin Med. 2020. Vol. 2. P. 1709–1712. DOI: 10.1007/s42399-020-00487-7

[17] Bolevich SB, Bolevich SS. Complex mechanism of COVID-19 development. Sechenov Medical Journal. 2020;11(2):50–61. (In Russ.) DOI: 10.47093/2218-7332.2020.11.2.50-61

[18] Болевич С.Б., Болевич C.C. Комплексный механизм развития СOVID-19 // Сеченовский вестник. 2020. Т. 11, № 2. С. 50–61. DOI: 10.47093/2218- 7332.2020.11.2.50-61

[19] Wang J, Wang BJ, Yang JC, et al. Research advances in the mechanism of pulmonary fibrosis induced by coronavirus disease 2019 and the corresponding therapeutic measures. Zhonghua Shao Shang Za Zhi. 2020;36(8):691–697. (In Chinese). DOI: 10.3760/cma.j.cn501120- 20200307-00132

[20] Wang J., Wang B.J., Yang J.C., et al. Research advances in the mechanism of pulmonary fibrosis induced by coronavirus disease 2019 and the corresponding therapeutic measures // Zhonghua Shao Shang Za Zhi. 2020. Vol. 36, No. 8. P. 691–697. DOI: 10.3760/cma.j.cn501120- 20200307-00132

[21] Vasarmidi E, Tsitoura E, Spandidos DA, et al. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review). Exp Ther Med. 2020;20(3):2557–2560. DOI: 10.3892/etm.2020.8980

[22] Vasarmidi E., Tsitoura E., Spandidos D.A., et al. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review) // Exp Ther Med. 2020. Vol. 20, No. 3. P. 2557–2560. DOI: 10.3892/etm.2020.8980

[23] Oronsky B, Larson C, Hammond TC, et al. A Review of Persistent Post-COVID Syndrome (PPCS). Clin Rev Allergy Immunol. 2021:1–9. DOI: 10.1007/s12016-021-08848-3

[24] Oronsky B., Larson C., Hammond T.C., et al. A Review of Persistent Post-COVID Syndrome (PPCS) // Clin Rev Allergy Immunol. 2021. P. 1–9. DOI: 10.1007/s12016-021-08848-3

[25] Gosudarstvennyi reestr lekarstvennykh sredstv [Internet]. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Longidaza® (Longidaza®) [cited 2021 Dec 26]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=dc89faa2-d6d5-4d31-9c40-9255e6d71284&t= (In Russ.)

[26] Государственный реестр лекарственных средств [Электронный ресурс]. Инструкция по медицинскому применению лекарственного препарата Лонгидаза (Longidaza) [дата обращения: 26.12.2021]. Доступно по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=dc89faa2-d6d5-4d31-9c40-9255e6d71284&t=

[27] Chernyavskaya OA, Osipov AV. Pathogenetic bases of the use of antifibrotic therapy with Bovhyaluronidazum azoximerum in patients with new coronavirus infection COVID-19. Medical Council. 2021;(12):154–160. (In Russ.) DOI: 10.21518/2079-701X-2021-12-154-160

[28] Чернявская О.А., Осипов А.В. Патогенетические основы применения антифибротической терапии бовгиалуронидазы азоксимером у больных новой коронавирусной инфекцией COVID-19 // Медицинский совет. 2021. № 12. С. 154–160. DOI: 10.21518/2079-701X-2021-12-154-160

RIGHTS & PERMISSIONS

Eco-Vector